Company Overview and News

20
HH / Hooper Holmes, Inc. 8-K (Current Report)

2018-06-04 sec.gov
Document UNITED STATES
HH

14
HH / Hooper Holmes, Inc. 8-K (Current Report)

2018-05-24 sec.gov
Document UNITED STATES
HH

24
HH / Hooper Holmes, Inc. 8-K (Current Report)

2018-05-03 sec.gov
Document UNITED STATES
HH

22
HH / Hooper Holmes, Inc. 10-K/A (Annual Report)

2018-05-01 sec.gov
Document UNITED STATES
HH

26
HH / Hooper Holmes, Inc. 10-K (Annual Report)

2018-04-17 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
HH

20
HH / Hooper Holmes, Inc. NT 10-K

2018-03-30 sec.gov
Document UNITED STATES
HH

17
HH / Hooper Holmes, Inc. 8-K (Current Report)

2018-03-30 sec.gov
Document UNITED STATES
HH

17
SWK Holdings Corporation Announces 2017 Fourth Quarter and Full-Year Financial Results

2018-03-29 globenewswire
• Total revenues of $37.5 million for the fiscal year 2017 compared to $22.4 million for the fiscal year 2016.
SWKH CGIX HPHW HH

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Silicon Investor Message Boards

This table lists all message boards related to HH / Hooper Holmes, Inc. on message board site Silicon Investor.

ahhahau0027s ahs HHS.C - Hi Ho Silver Resources Inc.
Hannover House, Inc. (HHSE) Ahh Canada - 2 out of 3 ainu0027t bad
Roche Holdings (ROHHY) Harte-Hanks Inc [NYSE: HHS] Is Not Just Penny Saver
Aahh...iNEXTV (AXC) The NEXT Thing! ABHH
Stuart Energy HHO-TSE Stuart Energy (HHO.TO) (SRNYF.PK)
CUSIP: 439104100